Free Trial

CureVac (CVAC) Short Interest Ratio & Short Volume

CureVac logo
$4.16 -0.11 (-2.46%)
As of 11:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CureVac Short Interest Data

CureVac (CVAC) has a short interest of 4.89 million shares, representing 5.20% of the float (the number of shares available for trading by the public). This marks a -2.00% decrease in short interest from the previous month. The short interest ratio (days to cover) is 7.5, indicating that it would take 7.5 days of the average trading volume of 698,383 shares to cover all short positions.

Current Short Interest
4,890,000 shares
Previous Short Interest
4,990,000 shares
Change Vs. Previous Month
-2.00%
Dollar Volume Sold Short
$16.72 million
Short Interest Ratio
7.5 Days to Cover
Last Record Date
May 15, 2025
Outstanding Shares
224,338,000 shares
Float Size
93,990,000 shares
Short Percent of Float
5.20%
Today's Trading Volume
157,062 shares
Average Trading Volume
698,383 shares
Today's Volume Vs. Average
22%
Short Selling CureVac?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for CureVac and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

CVAC Short Interest Over Time

CVAC Days to Cover Over Time

CVAC Percentage of Float Shorted Over Time

CureVac Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/15/20254,890,000 shares $16.72 million -2.0%5.2%7.5 $3.42
4/30/20254,990,000 shares $17.71 million +4.0%5.3%7.9 $3.55
4/15/20254,800,000 shares $15.50 million -1.0%5.1%7.7 $3.23
3/31/20254,850,000 shares $13.43 million +19.5%5.2%6 $2.77
3/15/20254,060,000 shares $12.22 million +3.8%4.3%5.1 $3.01
2/28/20253,910,000 shares $12.12 million +4.6%4.2%4.8 $3.10
2/15/20253,740,000 shares $13.65 million +2.8%4.0%4.7 $3.65
1/31/20253,640,000 shares $13.80 million -3.5%3.9%4.6 $3.79
1/15/20253,770,000 shares $15.34 million -1.3%4.0%5 $4.07
12/31/20243,820,000 shares $13.03 million -3.1%4.1%5.5 $3.41
12/15/20243,940,000 shares $12.45 million -6.4%4.2%7.8 $3.16
11/30/20244,210,000 shares $12.08 million -4.5%4.5%8.6 $2.87
11/15/20244,410,000 shares $11.20 million -3.3%4.7%9.3 $2.54
10/31/20244,560,000 shares $12.49 million -3.2%4.9%10.2 $2.74
10/15/20244,710,000 shares $13.24 million -1.7%5.0%9.6 $2.81
9/30/20244,790,000 shares $14.08 million -13.1%5.1%8.1 $2.94
9/15/20245,510,000 shares $18.95 million -0.5%5.9%7.2 $3.44
8/31/20245,540,000 shares $17.40 million -2.0%6.0%6.6 $3.14
8/15/20245,650,000 shares $18.36 million -10.0%6.1%5 $3.25
7/31/20246,280,000 shares $23.68 million -16.2%6.7%4.8 $3.77
7/15/20247,490,000 shares $26.96 million +22.8%8.0%5.7 $3.60
6/30/20246,100,000 shares $20.74 million +3.6%6.6%4.8 $3.40
6/15/20245,890,000 shares $21.62 million +17.8%6.3%5 $3.67
5/31/20245,000,000 shares $19.45 million +38.1%5.4%4.3 $3.89
5/15/20243,620,000 shares $11.55 million -17.5%3.9%3.7 $3.19
4/30/20244,390,000 shares $11.06 million +4.8%4.8%5.5 $2.52
4/15/20244,190,000 shares $11.10 million -16.4%4.6%5.3 $2.65
3/31/20245,010,000 shares $15.18 million +3.1%5.5%6.1 $3.03
3/15/20244,860,000 shares $16.04 million +10.7%5.3%5.5 $3.30
2/29/20244,390,000 shares $15.01 million +3.1%4.8%3.5 $3.42
2/15/20244,260,000 shares $14.74 million +2.9%4.7%3.6 $3.46
1/31/20244,140,000 shares $14.86 million -1.2%4.5%3.7 $3.59
1/15/20244,190,000 shares $16.26 million +1.7%4.6%4 $3.88
12/31/20234,120,000 shares $17.35 million +9.9%4.5%4.1 $4.21
12/15/20233,750,000 shares $22.95 million -11.6%4.1%3.7 $6.12
11/30/20234,240,000 shares $22.90 million +2.7%4.6%8.8 $5.40
11/15/20234,130,000 shares $22.84 million -3.7%4.5%9.5 $5.53
10/31/20234,290,000 shares $22.74 million +1.7%4.7%9.3 $5.30
10/15/20234,220,000 shares $25.02 million +1.0%4.6%9.6 $5.93
9/30/20234,180,000 shares $28.55 million -8.5%4.6%9.3 $6.83
The End of Elon Musk…? (Ad)

The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.

Click here to see why the "End of Elon" crowd is about to be wrong again.
9/15/20234,570,000 shares $36.61 million -7.7%5.0%10.8 $8.01
8/31/20234,950,000 shares $44.20 million +2.1%5.4%8.8 $8.93
8/15/20234,850,000 shares $44.86 million +0.2%5.3%7.5 $9.25
7/31/20234,840,000 shares $44.92 million -1.6%5.3%7.2 $9.28
7/15/20234,920,000 shares $48.66 million +12.3%5.4%7.1 $9.89
6/30/20234,380,000 shares $45.64 million +5.0%4.8%6.6 $10.42
6/15/20234,170,000 shares $41.45 million -0.7%4.5%6.7 $9.94
5/31/20234,200,000 shares $40.53 million -2.6%4.5%8.1 $9.65
5/15/20234,310,000 shares $38.40 million +19.4%4.6%7.7 $8.91
4/30/20233,610,000 shares $26.61 million -11.5%3.9%4.9 $7.37
4/15/20234,080,000 shares $31.78 million -0.7%4.5%5.1 $7.79
3/31/20234,110,000 shares $28.65 million +13.5%4.5%3.5 $6.97
3/15/20233,620,000 shares $25.34 million +2.8%4.0%3 $7.00
2/28/20233,520,000 shares $30.41 million +11.0%3.9%2.9 $8.64
2/15/20233,170,000 shares $28.09 million -26.3%4.8%2.7 $8.86
1/31/20234,300,000 shares $46.18 million No Change7.6%3.8 $10.74
1/15/20234,300,000 shares $44.03 million +75.5%7.6%5 $10.24
12/30/20222,450,000 shares $14.77 million +20.7%4.4%3.8 $6.03
12/15/20222,030,000 shares $13.74 million -2.9%3.6%4.8 $6.77
11/30/20222,090,000 shares $15.15 million -7.5%2.9%6.1 $7.25
11/15/20222,260,000 shares $18.24 million -13.4%3.2%6.7 $8.07
10/31/20222,610,000 shares $19.00 million -3.0%4.8%8.7 $7.28
10/15/20222,690,000 shares $20.23 million -5.9%4.9%8.6 $7.52
9/30/20222,860,000 shares $22.54 million -17.3%5.3%8.7 $7.88
9/15/20223,460,000 shares $33.35 million +5.2%6.4%7.1 $9.64
8/31/20223,290,000 shares $32.37 million +6.1%6.1%6.3 $9.84
8/15/20223,100,000 shares $41.48 million +5.4%5.8%5.3 $13.38
7/31/20222,940,000 shares $38.22 million -6.1%5.5%4.6 $13.00
7/15/20223,130,000 shares $39.50 million -28.9%5.8%4.7 $12.62
6/30/20224,400,000 shares $59.88 million -21.3%8.2%6.3 $13.61
6/15/20225,590,000 shares $75.19 million +0.2%10.4%9.1 $13.45
5/31/20225,580,000 shares $104.90 million -24.4%10.4%10.2 $18.80
5/15/20227,380,000 shares $115.57 million -3.7%13.6%13.7 $15.66
4/30/20227,660,000 shares $130.91 million +0.1%14.1%14.5 $17.09
4/15/20227,650,000 shares $133.34 million +12.5%14.1%13 $17.43
3/31/20226,800,000 shares $133.35 million -1.7%12.5%10.6 $19.61
3/15/20226,920,000 shares $114.32 million +0.3%12.7%10.5 $16.52
2/28/20226,900,000 shares $116.06 million +3.9%12.7%9.9 $16.82
2/15/20226,640,000 shares $115.07 million +11.6%12.2%8.7 $17.33
1/31/20225,950,000 shares $114.89 million +39.7%11.0%7.9 $19.31
1/15/20224,260,000 shares $104.28 million +2.4%7.9%5.9 $24.48
12/31/20214,160,000 shares $142.73 million +17.2%7.7%5.7 $34.31
12/15/20213,550,000 shares $140.30 million -4.8%6.6%4.9 $39.52
11/30/20213,730,000 shares $179.86 million -8.4%6.9%5.4 $48.22
11/15/20214,070,000 shares $146.52 million -0.7%7.6%6.5 $36.00
10/29/20214,100,000 shares $164.29 million -8.7%7.6%6.1 $40.07
10/15/20214,490,000 shares $178.79 million +3.9%9.7%6.6 $39.82
9/30/20214,320,000 shares $235.96 million -4.9%8.2%6.6 $54.62
9/15/20214,540,000 shares $256.01 million -2.2%8.6%5.9 $56.39
8/31/20214,640,000 shares $305.45 million +2.0%8.8%3.8 $65.83
The End of Elon Musk…? (Ad)

The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.

Click here to see why the "End of Elon" crowd is about to be wrong again.
8/13/20214,550,000 shares $267.54 million +12.4%8.6%3.6 $58.80
7/30/20214,050,000 shares $199.50 million +11.6%7.7%3.1 $49.26
7/15/20213,630,000 shares $185.13 million -12.7%6.9%2.5 $51.00
6/30/20214,160,000 shares $305.68 million +41.5%7.9%2.7 $73.48
6/15/20212,940,000 shares $288.71 million -0.3%5.6%2.1 $98.20
5/28/20212,950,000 shares $328.87 million -7.5%5.6%2.9 $111.48
5/14/20213,190,000 shares $326.50 million +64.4%6.0%3.1 $102.35
4/30/20211,940,000 shares $223.12 million +16.9%3.6%1.8 $115.01
4/15/20211,660,000 shares $170.33 million +20.3%3.1%1.7 $102.61
3/31/20211,380,000 shares $122.49 million +3.0%2.6%1.6 $88.76
3/15/20211,340,000 shares $117.64 million +31.4%2.5%1.6 $87.79
2/26/20211,020,000 shares $94.83 million +51.8%2.2%1.3 $92.97
2/12/2021672,000 shares $77.00 million -46.2%1.5%0.9 $114.58
1/29/20211,250,000 shares $105.66 million +9.7%2.7%1.6 $84.53
1/15/20211,140,000 shares $114.67 million No Change2.6%1.9 $100.59

CVAC Short Interest - Frequently Asked Questions

What is CureVac's current short interest?

Short interest is the volume of CureVac shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 4,890,000 shares of CVAC short. 5.20% of CureVac's shares are currently sold short. Learn More on CureVac's current short interest.

What is a good short interest ratio for CureVac?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CVAC shares currently have a short interest ratio of 8.0. Learn More on CureVac's short interest ratio.

Which institutional investors are shorting CureVac?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of CureVac: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for CureVac?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.20% of CureVac's floating shares are currently sold short.

Is CureVac's short interest increasing or decreasing?

CureVac saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 4,890,000 shares, a decline of 2.0% from the previous total of 4,990,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is CureVac's float size?

CureVac currently has issued a total of 224,338,000 shares. Some of CureVac's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. CureVac currently has a public float of 93,990,000 shares.

How does CureVac's short interest compare to its competitors?

5.20% of CureVac's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to CureVac: Merus (8.68%), Rhythm Pharmaceuticals, Inc. (8.74%), Akero Therapeutics, Inc. (9.80%), Avidity Biosciences, Inc. (13.74%), PTC Therapeutics, Inc. (7.09%), Cytokinetics, Incorporated (13.36%), Sarepta Therapeutics, Inc. (10.02%), Krystal Biotech, Inc. (10.52%), ACADIA Pharmaceuticals Inc. (12.77%), SpringWorks Therapeutics, Inc. (8.67%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks.

What does it mean to sell short CureVac stock?

Short selling CVAC is an investing strategy that aims to generate trading profit from CureVac as its price is falling. CVAC shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against CureVac?

A short squeeze for CureVac occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CVAC, which in turn drives the price of the stock up even further.

How often is CureVac's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CVAC, twice per month. The most recent reporting period available is May, 15 2025.




This page (NASDAQ:CVAC) was last updated on 6/11/2025 by MarketBeat.com Staff
From Our Partners